Volume 18, Issue 4 pp. 209-215

Structural and neurochemical markers of brain injury in the migraine diathesis of systemic lupus erythematosus

CL Rozell

CL Rozell

Department of Nuerology, The University of New Mexico Health Sciences Center, Albuquerque, NM, USA;

Search for more papers by this author
WL Sibbitt Jr

Corresponding Author

WL Sibbitt Jr

Department of Internal Medicine, The University of New Mexico Health Sciences Center, Albuquerque, NM, USA;

Center for Non-Invasive Diagnosis, The University of New Mexico Health Sciences Center, Albuquerque, NM, USA

Wilmer L Sibbitt Jr, Department of Internal Medicine, Division of Clinical Immunology and Rheumatic Diseases, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA. Tel: +1 505 272 4761, fax: +1 505 272 4628.Search for more papers by this author
WM Brooks

WM Brooks

Department of Neurosciences, The University of New Mexico Health Sciences Center, Albuquerque, NM, USA; and the

Center for Non-Invasive Diagnosis, The University of New Mexico Health Sciences Center, Albuquerque, NM, USA

Search for more papers by this author
First published: 04 January 2002
Citations: 7

Abstract

Objective: To determine whether migraine in systemic lupus erythematosus (SLE) is associated with accentuated brain injury and disease activity. Methods: Forty SLE patients (11 without headache, 11 with non-migraine headache, and 18 with migraine) underwent clinical evaluation, magnetic resonance imaging (MRI), and spectroscopy (MRS). Results: Recurrent headache occurred in 75% of SLE patients. MRI abnormalities and reduced N-acetylaspartate were common. However, migraine in SLE was not associated with increased disease activity or severity, neuropsychiatric manifestations, or end-organ involvement compared to patients without migraine (p>0.05). There were no differences in the prevalence or severity of MRI or MRS abnormalities between SLE patients with migraine, with non-migraine headache, or without headache (p>0.05). Conclusions: Headache does not identify SLE patients at risk for brain injury, increased disease activity, or increased end-organ involvement. Aggressive immunosuppressive therapy for headache alone is not indicated in SLE.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.